Freenome's PREEMPT CRC study, involving 48,995 participants, represents the largest prospective study of a blood-based colorectal cancer screening test and met all primary efficacy endpoints.

Evaxion Biotech has completed dosing in its Phase 2 trial of EVX-01, a personalized cancer vaccine, for advanced melanoma treatment.

Phase 2 PROFECTA-II/GOG-3044 trial shows afuresertib plus paclitaxel did not significantly improve progression-free or overall survival compared to paclitaxel alone in platinum-resistant ovarian cancer patients.

Caris Life Sciences has raised $168 million in a growth capital funding round led by Braidwell LP, bringing their total capital raised since 2018 to $1.86 billion.

Phase 3 POD1UM-303 trial shows retifanlimab combined with chemotherapy significantly improves progression-free survival in patients with locally recurrent or metastatic squamous cell anal carcinoma (SCAC).

CAR T therapy is recommended before bispecific antibodies in RRMM due to its potential for durable and deep responses, according to IMWG and ASCO guidelines.

Narsoplimab significantly reduced the risk of mortality in high-risk TA-TMA patients by over 3-fold compared to an external control group.

AstraZeneca's oral PCSK9 inhibitor, AZD0780, demonstrated a 52% reduction in LDL cholesterol when added to statin therapy in a Phase 1 trial.

An exploratory analysis from the phase 3 CALLA trial demonstrated that undetectable circulating tumor DNA (ctDNA) at cycle 6 was associated with a 95% reduction in risk of disease progression or death in patients with locally advanced cervical cancer.

Updated data from the CARTITUDE-4 trial shows cilta-cel significantly improves overall survival in lenalidomide-refractory multiple myeloma patients compared to standard of care.

Bicistronic CD19/CD22-directed CAR T-cell therapy (B019) demonstrates safety and high remission rates in children with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL).

Azafaros has raised €132 million in an oversubscribed Series B financing round led by Jeito Capital and co-led by Forbion Growth to advance two Phase 3 clinical programs for nizubaglustat.

Real-world evidence (RWE) is revolutionizing drug development by providing crucial data from patient experiences outside traditional clinical trials, helping bring safer and more effective treatments to market.

The S2302 Pragmatica-Lung trial represents a groundbreaking "dramatically streamlined" phase III study evaluating ramucirumab plus pembrolizumab in advanced non-small cell lung cancer patients whose disease progressed on prior immunotherapy.

The European Medicines Agency's CHMP recommended CAPVAXIVE for active immunization against invasive pneumococcal disease and pneumonia in adults 18 and older.

Final analysis of COSMIC-313 phase 3 trial demonstrates sustained progression-free survival benefit with cabozantinib-nivolumab-ipilimumab combination in advanced RCC patients.

Leading experts at SOHO 2024 discuss critical strategies for managing toxicities in chronic lymphocytic leukemia patients treated with BCL2 and BTK inhibitors, emphasizing patient-specific approaches.

Vyloy (zolbetuximab) has emerged as the first approved Claudin 18.2-targeted therapy for HER2-negative gastric and gastroesophageal junction adenocarcinoma, marking a significant milestone in precision oncology.

Osivax has dosed the first participant in a Phase 2a clinical trial evaluating OVX836 as a booster for its broad-spectrum influenza vaccine candidate.

The AURIGA trial demonstrated a significantly higher MRD-negative conversion rate at 12 months with daratumumab plus lenalidomide compared to lenalidomide alone (50.5% vs 10.8%).